Exploring proteomic plasma biomarkers in eosinophilic and neutrophilic asthma. Issue 2 (26th September 2022)

• Record Type: Journal Article
• Authors: Kere, Maura; Klevebro, Susanna; Hernandez‐Pacheco, Natalia; Ödling, Maria; Ekström, Sandra; Mogensen, Ida; Janson, Christer; Palmberg, Lena; van Hage, Marianne; Georgelis, Antonios; Bergström, Anna; Kull, Inger; Melén, Erik; Björkander, Sophia
• Is Part Of: Clinical & experimental allergy. Volume 53:Issue 2(2023)
• Page Start: 186
• Page End: 197
• Publication Date: 2022-09-26
• Subjects: asthma -- biomarkers -- eosinophils -- neutrophils -- plasma -- proteins; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.14229
• Languages: English
• ISSNs: 0954-7894

Abstract

Abstract: Background: Few biomarkers identify eosinophilic and neutrophilic asthma beyond cell concentrations in blood or sputum. Finding novel biomarkers for asthma endotypes could give insight about disease mechanisms and guide tailored treatment. Our aim was to investigate clinical characteristics and inflammation‐related plasma proteins in relation to blood eosinophil and neutrophil concentrations in subjects with and without asthma. Methods: We included 24–26‐year‐old subjects ( n = 2063) from the Swedish population‐based cohort BAMSE. Subjects with asthma ( n = 239) and without asthma ( n = 1824) were subdivided based on blood eosinophil and neutrophil concentrations (cut‐offs 0.3 × 10 9 /L and 5.0 × 10 9 /L, respectively). We measured the levels of 92 plasma proteins using Olink Proseek Multiplex Inflammation Panel Assay. Group statistics tests were used to analyse the data, as well as adjusted multiple logistic regression models. Results: Among subjects with asthma, 21.8% had eosinophilic asthma and 20.5% neutrophilic asthma. Eosinophilic asthma, but not neutrophilic asthma, was associated with a distinct clinical phenotype with, for example, higher proportions of eczema and sensitization. Most plasma proteins that associated with high eosinophil and/or neutrophil blood concentrations in subjects with asthma showed similar associations in subjects without asthma. However, out of these proteins, MMP10 levels were associated with eosinophilic asthma and were significantly higher as compared to controls with high eosinophilic concentration, while CCL4 levels associated with high neutrophil concentration only in subjects with asthma. Conclusions: Eosinophilic asthma was associated with a clear clinical phenotype. With our definitions, we identified MMP10 as a possible plasma biomarker for eosinophilic asthma and CCL4 was linked to neutrophilic asthma. These proteins should be evaluated further in clinical settings and using sputum granulocytes to define the asthma endotypes.